Define Carcinoma of the Urinary Bladder. Describe its clinical features and management.

The Concept

Carcinoma of the bladder is usually a transitional cell (urothelial) carcinoma, arising from the lining of the bladder. It is commonest in older men and is strongly linked to carcinogens excreted in the urine — above all cigarette smoking and certain occupational chemicals. Its hallmark presentation, painless visible haematuria, is one of the most important 'red flag' symptoms in surgery.

Risk Factors & Types

Risk factors: smoking (the major cause), occupational exposure to aromatic amines (in the dye, rubber and chemical industries), chronic inflammation, and schistosomiasis. The histological type reflects the cause: transitional cell carcinoma is commonest; squamous cell carcinoma arises with chronic irritation or schistosomiasis; and adenocarcinoma is rare.

Clinical Features

The cardinal symptom is painless, visible (macroscopic) haematuria — which must always be investigated to exclude cancer. There may also be recurrent urinary infections and irritative LUTS; advanced disease causes pain, a mass, and ureteric obstruction.

Investigation & Staging

Cystoscopy with biopsy is the gold-standard investigation, allowing direct visualisation and tissue diagnosis; urine cytology and CT urography (which also images the upper tracts and stages the disease) complete the work-up. The crucial staging distinction is between non-muscle-invasive and muscle-invasive disease, as this determines treatment.

Management

• Non-muscle-invasive disease — transurethral resection of the bladder tumour (TURBT) plus intravesical therapy (BCG or mitomycin), with regular surveillance cystoscopy (recurrence is common).
• Muscle-invasive disease — radical cystectomy with urinary diversion (e.g. An ileal conduit), often with neoadjuvant chemotherapy, or radical radiotherapy.
• Metastatic disease — chemotherapy.

WHY It Recurs — the 'field Change'

A defining feature of urothelial (transitional cell) cancer is that the entire urothelial lining — from the renal pelvis through the ureters to the bladder and urethra — has been exposed to the same carcinogens, a 'field change'. This is why bladder cancer is characteristically multifocal and recurrent, why lifelong surveillance cystoscopy is needed after treatment, and why the upper tracts are also imaged (CT urogram) to look for synchronous tumours. Understanding the field change explains the whole follow-up strategy.

Intravesical Therapy Explained

For non-muscle-invasive disease, intravesical therapy after TURBT reduces recurrence and progression. Intravesical BCG (an immunotherapy that provokes a local immune response) is used for higher-risk disease and carcinoma in situ, while intravesical chemotherapy (mitomycin C) is used for lower-risk tumours. This local, bladder-directed treatment delivers high drug concentrations to the at-risk urothelium while limiting systemic effects — a neat example of matching treatment to the field-change biology.

Muscle-invasive Disease & Diversion

The step up to muscle-invasive disease is the critical prognostic watershed. It is treated by radical cystectomy (with pelvic lymphadenectomy) plus urinary diversion — most often an ileal conduit (a segment of ileum bringing the ureters to a stoma), or a neobladder in selected patients — usually with neoadjuvant chemotherapy; bladder-preserving radical radiotherapy is an alternative. Counselling about the stoma and its consequences is a major part of care, underlining why the non-muscle-invasive versus muscle-invasive distinction governs everything.

A Note on Upper-tract Urothelial Tumours

Because the whole urothelium shares the field change, urothelial (transitional cell) carcinoma can also arise in the renal pelvis and ureter, not just the bladder. Such upper-tract tumours also present with visible haematuria (and sometimes loin pain from clot obstruction), are imaged by CT urography and ureteroscopy, and are classically treated by nephro-ureterectomy (removing the kidney and the whole ureter with a bladder cuff, because of the multifocal field risk). This is why investigating haematuria always includes imaging the upper tracts, not just cystoscopy of the bladder.

• Painless visible haematuria = bladder cancer until proven otherwise → cystoscopy.
• Transitional cell (smoking, aromatic amines) commonest; squamous cell with schistosomiasis/chronic irritation.
• Non-muscle-invasive → TURBT + intravesical BCG/mitomycin + surveillance; muscle-invasive → radical cystectomy (± neoadjuvant chemo) or radiotherapy.

Painless gross haematuria is bladder cancer until proved otherwise.

• Bladder cancer = usually transitional cell (urothelial) carcinoma; older men; from urinary carcinogens.
• Risk: smoking (major), occupational aromatic amines, chronic inflammation/schistosomiasis (→ squamous cell carcinoma).
• Hallmark: painless visible haematuria — always investigate (exclude cancer).
• Cystoscopy + biopsy (gold standard) + urine cytology + CT urogram; key divide = non-muscle-invasive vs muscle-invasive.
• Non-muscle-invasive: TURBT + intravesical BCG/mitomycin + surveillance; muscle-invasive: radical cystectomy (+ diversion) ± neoadjuvant chemo, or radiotherapy.